Surgical analysis of tumor-related epilepsy

Low-grade gliomas (LGGs) account for about 15% of primary brain tumors, while up to 80% of LGG patients have seizures, 40% of which are drug resistant and have significant complications that lead to a decline in quality of lifeTumor-related epilepsy is a difficult problem in neuro-internal medicine, which is different in epidemiology, pathology, pathophysiology, clinical characteristics and prognosisTherefore, its treatment must also be different from the treatment of simple epilepsy or simple tumorsJKim et alreviewed the effects of epilepsy surgery and neurosurgery on the prognosis of such patients, and the results were published in the January 2019 issue of Journal of Clinical Sciencestudy methods
collected data on 48 patients treated at Westmead Hospital over a 10-year timeThe patients had seizures first and then low-level gliomas were found, and were treated by the Epilepsy Surgery Group or the Neurosurgery Group, respectivelyThe main indicators of the results of the study were the Patient Engel Grading (Engel Iand II), and secondary outcome indicators, including surgical delay time, lesions histological examination results, degree of lesions removal, lesions recurrence and postoperative dysfunctionthe results of the studystudies found that Engel I and II were significantly higher in the epilepsy surgical group compared to patients in the neurosurgery group (OR?13.2; 95% CI, 1.239-140.679; P.0.033)Epilepsy surgery patients received significant delays in the duration of surgery (36 months vs0.5 months; P 0.001)The rate of lesions removed in the epilepsy surgical group was significantly higher than that of the neurosurgery group (127% vs73% ;P There was no significant difference in recurrence rates between the two groups conclusions studies show that tumor-related epilepsy patients through preoperative evaluation, extensive removal of eclampsia lesions, is conducive to the control of seizures.